Suppr超能文献

用于检测凝血因子V莱顿突变和凝血酶原G20210A的引物工程化多重聚合酶链反应-限制性片段长度多态性分析评估

Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A.

作者信息

Huber S, McMaster K J, Voelkerding K V

机构信息

Department of Pathology and Laboratory Medicine, University of Wisconsin Medical School, Madison 53792, USA.

出版信息

J Mol Diagn. 2000 Aug;2(3):153-7. doi: 10.1016/S1525-1578(10)60631-9.

Abstract

Factor V Leiden and prothrombin G20210A are clinically relevant genetic risk factors for venous thrombosis. Analysis for both mutations is increasingly being performed on patients exhibiting hypercoagulability. The goal of the current study was to evaluate the performance of primer-engineered multiplex polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for the simultaneous detection of factor V Leiden and prothrombin G20210A. Primer-engineered multiplex PCR-RFLP methods for the detection of factor V Leiden and prothrombin G20210A from the medical literature were reviewed. A modified method was optimized in which both mutations generate HindIII RFLPs and the prothrombin amplicon contains an invariant HindIII recognition site to assess the completeness of endonuclease digestion. Digested amplification products were analyzed by agarose gel electrophoresis in a single gel lane and visualized by ethidium bromide. Primer-engineered multiplex PCR-RFLP was used to analyze 205 human genomic DNA samples whose factor V Leiden genotypes had been previously determined by MnlI PCR-RFLP. Complete concordance for factor V Leiden genotypes was observed between the two methods in the 205-sample cohort comprising 139 wild-type, 62 heterozygous mutant, and four homozygous mutant individuals. For prothrombin G20210A, primer-engineered multiplex PCR-RFLP identified 196 wild-type and nine heterozygous mutant individuals in the 205-sample cohort. To independently verify prothrombin genotypes, the nine heterozygous mutants and an additional 11 wild-type patient samples (representing 10% of patient samples) were subjected to DNA sequencing. Complete concordance was observed between DNA sequencing and primer-engineered multiplex PCR-RFLP results. In further validation, 123 of the DNA samples consisting of four heterozygous mutant and 119 wild type individuals were genotyped with the Invader Assay for Factor II (prothrombin G20210A). Results showed 100% concordance between the Invader Assay and primer-engineered multiplex PCR-RFLP. A primer-engineered multiplex PCR-RFLP based on single restriction endonuclease digestion has been evaluated and shown to simultaneously and accurately detect factor V Leiden and prothrombin G20210A mutations. The method is robust and readily adaptable to the clinical molecular diagnostic laboratory.

摘要

因子V莱顿突变和凝血酶原G20210A是静脉血栓形成的临床相关遗传风险因素。对于表现出高凝性的患者,越来越多地对这两种突变进行分析。本研究的目的是评估引物工程多重聚合酶链反应-限制性片段长度多态性(PCR-RFLP)同时检测因子V莱顿突变和凝血酶原G20210A的性能。我们回顾了医学文献中用于检测因子V莱顿突变和凝血酶原G20210A的引物工程多重PCR-RFLP方法。优化了一种改良方法,其中两种突变均产生HindIII RFLP,并且凝血酶原扩增子包含一个不变的HindIII识别位点,以评估核酸内切酶消化的完整性。消化后的扩增产物在单个凝胶泳道中通过琼脂糖凝胶电泳进行分析,并用溴化乙锭进行可视化。引物工程多重PCR-RFLP用于分析205份人类基因组DNA样本,这些样本的因子V莱顿基因型先前已通过MnlI PCR-RFLP确定。在由139名野生型、62名杂合突变型和4名纯合突变型个体组成的205个样本队列中,两种方法在因子V莱顿基因型上完全一致。对于凝血酶原G20210A,引物工程多重PCR-RFLP在205个样本队列中鉴定出196名野生型和9名杂合突变型个体。为了独立验证凝血酶原基因型,对9名杂合突变型和另外11名野生型患者样本(占患者样本的10%)进行了DNA测序。DNA测序结果与引物工程多重PCR-RFLP结果完全一致。在进一步验证中,对由4名杂合突变型和

相似文献

引用本文的文献

3
Risk factors for deep vein thrombosis of lower extremities in Sudanese women.苏丹女性下肢深静脉血栓形成的危险因素
Vasc Health Risk Manag. 2018 Aug 20;14:157-164. doi: 10.2147/VHRM.S170556. eCollection 2018.
6
Screening Donors for Rare Antigen Constellations.筛选具有罕见抗原组合的献血者。
Transfus Med Hemother. 2009;36(3):199-203. doi: 10.1159/000218110. Epub 2009 May 26.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验